Atrioventricular (AV) conduction abnormalities are common and potentially lethal if not treated with a
pacemaker. We recently discovered that macrophages inhabit the mouse and human AV node, and that
depletion of macrophages in the Cd11bDTR mouse leads to complete AV block. In the normal murine AV node,
macrophages electrically couple to conducting cells via connexin 43. This electrotonic coupling creates a
source-sink relationship between macrophages and conducting cardiomyocytes. Genetic interference with
macrophage-myocyte coupling weakened AV conduction while optogenetically enhanced communication
improved AV node function. These data, which we recently published in Cell, establish that resident
macrophages augment the fidelity of AV node conduction. We have continued this work by performing survival
studies after macrophage depletion, finding that all mice with AV block die. In preliminary work for this
application, we adopted an implantable pacemaker system for mice, and were able to pace mice for several
weeks. We here propose to use this technique in Cd11bDTR mice. We will conduct studies to better understand
the function of AV node macrophages in order to advance our long-term translational goal to one day develop
macrophage-targeted therapeutics as a new option for conduction disorders. We will implant pacemakers into
Cd11bDTR mice and pace them for up to three months after macrophage depletion. We will test the hypothesis
that, if the mice are supported with a pacemaker, spontaneous recovery of AV node conduction will occur due
to recovery of tissue macrophages. We will test for AV node recovery by ECG telemetry in conjunction with in
vivo electrophysiological and ex vivo optical mapping studies to provide a comprehensive assessment of AV
node function. After recovery, we will isolate AV nodes to investigate the cellular and structural landscape with
special focus on macrophage numbers, subset heterogeneity and spatial distribution by FACS, single-cell
RNA-sequencing and imaging. Using parabiosis, we will determine whether cardiac macrophages repopulate
from circulating monocytes or from tissue progenitors. We will further test whether enhancing tissue
macrophage numbers will influence AV node recovery. Since AV node macrophages are reduced in mice
lacking macrophage colony stimulating factor (M-CSF), we will treat macrophage-depleted mice with M-CSF to
test the hypothesis that such treatment will increase local proliferation of remaining AV node macrophages, and
thus ushers in recovery of AV node conduction. We will also explore other growth hormones with influence on
myeloid cell replenishment. In a translational aim, we will study macrophages, other non-cardiomyocytes and
structural remodeling processes in human AV nodes obtained from patients with AV block. Our collaborative
application unites an interdisciplinary team with expertise in electrophysiology, immunology and
bioengineering. While the novel research plan is ambitious, we believe that our preliminary data demonstrate
feasibility and provide us with a unique opportunity to study a question with high clinical relevance.